P&G Backs Proposed SPF Cap For Sunscreens, In Break From Rivals
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble files comments in support of FDA’s proposed 50+ SPF cap for OTC sunscreens, maintaining that high-SPF products do not provide a significant incremental protective benefit. P&G also cites harmonization with international regulatory frameworks in comments to FDA.
You may also be interested in...
Senators Push FDA For SPF Cap, Spray Sunscreen Review
Nine Democrats led by Senator Jack Reed ask FDA to resolve sunscreen issues that remain in regulatory limbo. FDA needs to clarify “misconceptions about misleadingly high SPF labels beyond 50, where the increase in UV protection is relatively small,” the senators suggest.
CHPA: Sunscreen Efficacy Ceiling Is More Harmful Than SPF Claim Limit
FDA should not impose an efficacy ceiling on sunscreen formulations even if it caps sun protection factor label claims at 50 or 50+, industry stakeholders argue.
FDA Considers Capping SPF Values At 50+ Despite Efficacy Data
FDA might cap sun protection values at 50 or 50+ so as not to mislead consumers about the clinical benefit of sunscreens with higher SPF values, according to a proposed rule.